Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation

Clinical Infectious Diseases

Volumn 26, Issue 4, 1998, Pages 865-873

  De Otero, Jordi ^a   Gavaldà, Joan ^a,b   Murio, Enric ^a   Vargas, Victor ^a   Calicó, Ignasi ^a   Llopart, Lluis ^a   Rosselló, José ^a   Margarit, Carles ^a   Pahissa, Albert ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN A; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; OKT 3; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031916426     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/513949     Document Type: Article

References (22)

1. Bismuth H, Ericzon BG, Roles K, et al. Hepatic transplantation in Europe. Lancet 1987;2:674-5.
2. Rubin RH. Impact of cytomegalovirus infection in organ transplant recipients. Rev Infect Dis 1990;12(suppl 7):S754-66.
3. Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994;170:644-52.
4. '4. George MJ, Snydman DR, Werner BG, Dougherty N, Griffith J, CMVIG Study Group. Cytomegalovirus disease as a risk factor for fungal disease in orthotopic liver transplant (OLT) recipients [abstract 32]. In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy (Anaheim, California). Washington, DC: American Society for Microbiology, 1992.
5. Paya CV, Wiesner RH, Hermans PE, et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependant analysis. J Hepatol 1993;18:185-95.
6. Castaldo P, Stratta RJ, Wood RP, et al. Fungal disease in liver transplant recipients: a multivariate analysis of risk factors. Transplant Proc 1991;23:1517-9.
7. Tollemar J, Ericzon EB, Barkholt L, Andersson J, Ringden O, Groth CG. Risk factors for deep Candida infections in liver transplant recipients. Transplant Proc 1990;22:1826-7.
8. Kusne S, Torre-Cisneros J, Manez R, et al. Factors associated with invasive aspergillosis and the significance of positive Aspergillus culture after liver transplantation. J Infect Dis 1992;166:1379-83.
9. Paya CV, Wiessner RH, Hermans PE, et al. Lack of association between cytomegalovirus infection, HLA matching and the vanishing bile duct syndrome after liver transplantation. Hepatology 1992;16:66-70.
10. Bronsther O, Manez R, Kusne S, et al. Posttransplant B, non-A non-B, and cytomegalovirus hepatitis increase the risk of developing chronic rejection after liver transplantation. Transplant Proc 1995;27:1206-7.
11. Conti F, Dousset B, Archambeau D, et al. Enhanced risk of steroid-resistant acute rejection following pretransplant steroid therapy in liver graft recipients. Transplantation 1995;60:1104-8.
12. O'Grady JG, Alexander GJM, Sutherland S, et al. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile duct syndrome after liver transplantation. Lancet 1988;2:302-5.
13. Manez R, White LT, Linden P, et al. The influence of HLA matching on cytomegalovirus hepatitis and chronic rejection after liver transplantation. Transplantation 1993;55:1067-71.
14. de Otero J, Gavalda J, Vargas V, et al. Does cytomegalovirus (CMV) infection modify the histopathological expression of hepatitis C virus (HCV) infection after liver transplant (LT)? [abstract H75]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.
15. Rosen HR, Corless CL, Chou S, et al. Cytomegalovirus (CMV) infection associated with allograft cirrhosis and failure following liver transplantation for hepatitis C. Hepatology 1995;24(pt 2):421A.
16. Falagas ME, Snydman DR, Griffith J, et al. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. Ann Intern Med 1997;126:275-9.
17. Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation. N Engl J Med 1989;321:1014-22.
18. Cuervas-Mons V, Martinez AJ, Dekker A, Starzl TE, Van Thiel DH. Adult liver transplantation: an analysis of the early causes of death in 40 consecutive cases. Hepatology 1986;6:495-501.
19. Backman L, Gibbs J, Levy M, McMillan R, et al. Causes of graft loss after liver transplantation. Transplantation 1993;55:1078-82.
20. Eckhoff DE, Pirsch JD, D'Alessandro AM, et al. Pretransplant status and patient survival following liver transplantation. Transplantation 1995;60:920-5.
21. Delmonico FL, Jenkins RL, Freeman R, et al. The high-risk liver allograft recipient. Should allocation policy consider outcome? Arch Surg 1992;127:579-84.
22. Nikaein A, Backman L, Jennings L, et al. HLA compatibility and liver transplant outcome. Transplantation 1994;54:786-92.